Street Calls of the Week
SAN DIEGO - AnaptysBio, Inc. (NASDAQ:ANAB), a biotechnology company with a market capitalization of $652 million and impressive year-to-date returns of 78%, announced Monday that its Board of Directors has approved plans to explore separating its business into two independent, publicly traded companies by the end of 2026. According to InvestingPro data, the company’s stock has shown strong momentum with a 10% gain in the past week.
The proposed separation would create a royalty management company that will oversee royalties and milestone payments from existing financial collaborations, including Jemperli with GSK and imsidolimab with Vanda Pharmaceuticals. The second entity would operate as a biopharma company focused on developing immunology therapeutics for autoimmune and inflammatory diseases. InvestingPro analysis shows the company maintains a healthy liquidity position with a current ratio of 8.22, though it’s currently operating at a loss with negative EBITDA of $85.6 million in the last twelve months.
The royalty management company would manage the rights to Jemperli royalties, which range from 8% to 25% of net sales depending on revenue thresholds. GSK recently reported $262 million in Q2 2025 sales for Jemperli, showing over 19% quarter-over-quarter growth. GSK continues to project peak sales of approximately $2.7 billion for Jemperli in monotherapy indications.
The biopharma operations company would focus on developing rosnilimab, ANB033, and ANB101. Rosnilimab has completed a Phase 2b trial in rheumatoid arthritis and is currently in a Phase 2 trial for ulcerative colitis, with top-line data expected by December 2025. ANB033 is being studied in celiac disease, while ANB101 is in Phase 1a trials.
"Today’s announcement to explore a separation of our wholly owned biopharma programs from our royalty assets is intended to provide investors with the opportunity to realize and enhance the potential value of two distinct sets of assets," said Daniel Faga, president and CEO of AnaptysBio, who is expected to lead the biopharma company after the separation.
The separation is subject to final board approval and other customary conditions. The company stated that the biopharma company would launch with sufficient capital to fund operations for at least two years.
This announcement is based on a press release statement from AnaptysBio. The company’s stock has historically shown low correlation with broader market movements, with a beta of -0.18. For deeper insights into AnaptysBio’s financial health and additional ProTips, investors can access comprehensive analysis through InvestingPro, which offers exclusive metrics and expert recommendations.
In other recent news, AnaptysBio has been in the spotlight following concerns related to Eli Lilly’s PD-1 agonist, peresolimab. The concerns arose after a recent abstract from the American College of Rheumatology (ACR) revealed malignancy signals during a study. Specifically, two malignancies were reported in both the 400mg and 100mg treatment groups, while none were observed in the placebo or 100mg groups. In response to these developments, Truist Securities reiterated its Hold rating on AnaptysBio, maintaining a price target of $20.00. These updates have contributed to volatility in AnaptysBio’s stock. Investors are closely monitoring the situation as these findings could impact future research and development strategies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.